148 related articles for article (PubMed ID: 14997914)
21. Prophylaxis of post-ERCP pancreatic complications with gabexate.
Piscaglia F; Righini R; Tewelde AG
Dig Liver Dis; 2007 Mar; 39(3):291; author reply 291. PubMed ID: 17267312
[No Abstract] [Full Text] [Related]
22. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Kwon YH; Kim JY; Lee SJ; Jang SY; Park HW; Yang HM; Jung MK; Jeon SW; Cho CM; Tak WY; Kweon YO; Kim SK
Korean J Gastroenterol; 2012 Mar; 59(3):232-8. PubMed ID: 22460572
[TBL] [Abstract][Full Text] [Related]
23. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
[TBL] [Abstract][Full Text] [Related]
24. Acute pancreatitis.
Famularo G; Minisola G; De Simone C
N Engl J Med; 2006 Aug; 355(9):961; author reply 961. PubMed ID: 16943414
[No Abstract] [Full Text] [Related]
25. Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia: A systematic review and meta-analysis.
Wang G; Xiao G; Xu L; Qiu P; Li T; Wang X; Wen P; Wen J; Xiao X
Pancreatology; 2018 Jun; 18(4):370-378. PubMed ID: 29550097
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best?
Mariani A
JOP; 2003 Jan; 4(1):68-74. PubMed ID: 12555018
[TBL] [Abstract][Full Text] [Related]
27. [Can post-ERCP acute pancreatitis be predicted and prevented?].
Heyries L
Gastroenterol Clin Biol; 2001 Jan; 25(1 Suppl):1S241-6. PubMed ID: 11223596
[No Abstract] [Full Text] [Related]
28. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V
N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777
[TBL] [Abstract][Full Text] [Related]
29. [Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, non-randomized study].
Vila JJ; Jiménez FJ; Prieto C; Borobio E; Juanmartiñena JF; Borda F
Gastroenterol Hepatol; 2006 Apr; 29(4):231-6. PubMed ID: 16584693
[TBL] [Abstract][Full Text] [Related]
30. Prevention of ERCP-induced pancreatitis: success at last.
Pasricha P
Gastroenterology; 1997 Apr; 112(4):1415-7. PubMed ID: 9098032
[No Abstract] [Full Text] [Related]
31. [Meta-analysis: somatostatin for prophylaxis against post endoscopic retrograde cholangiopancreatography pancreatitis].
Pan SB; Geng XP
Zhonghua Wai Ke Za Zhi; 2016 Jun; 54(6):466-472. PubMed ID: 27938583
[No Abstract] [Full Text] [Related]
32. Pharmacological prevention of post-ERCP pancreatitis--an everlasting dream?
Hellmig S; Fölsch UR
Dig Liver Dis; 2006 Aug; 38(8):596-8. PubMed ID: 16731061
[No Abstract] [Full Text] [Related]
33. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
Testoni PA; Mariani A; Masci E; Curioni S
Dig Liver Dis; 2006 Aug; 38(8):588-95. PubMed ID: 16731060
[TBL] [Abstract][Full Text] [Related]
34. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.
Fujishiro H; Adachi K; Imaoka T; Hashimoto T; Kohge N; Moriyama N; Suetsugu H; Kawashima K; Komazawa Y; Ishimura N; Ishihara S; Amano Y; Kinoshita Y
J Gastroenterol Hepatol; 2006 Jun; 21(6):1065-9. PubMed ID: 16724996
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Pande H; Thuluvath P
Drugs; 2003; 63(17):1799-812. PubMed ID: 12921486
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Xie J; Li L
J Formos Med Assoc; 2021 Sep; 120(9):1796-1797. PubMed ID: 33895063
[No Abstract] [Full Text] [Related]
37. Preventing pancreatitis after endoscopic retrograde cholangiopancreatography.
Kubiliun NM; Elmunzer BJ
Gastrointest Endosc Clin N Am; 2013 Oct; 23(4):769-86. PubMed ID: 24079789
[TBL] [Abstract][Full Text] [Related]
38. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results.
Poon RT; Fan ST
JOP; 2003 Jan; 4(1):33-40. PubMed ID: 12555014
[TBL] [Abstract][Full Text] [Related]
39. Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?
Pezzilli R; Gabbrielli A; Labate AM; D'Alessio P; Barakat B; Costamagna G; Dibenedetti F; Massa M; Merlini G; d'Eril GM
Hepatogastroenterology; 2003; 50(51):851-5. PubMed ID: 12828103
[TBL] [Abstract][Full Text] [Related]
40. Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopancreatography.
Chan HH; Lai KH; Lin CK; Tsai WL; Lo GH; Hsu PI; Wei MC; Wang EM
J Chin Med Assoc; 2008 Dec; 71(12):605-9. PubMed ID: 19114324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
